Bio-Techne (TECH) Aandelenoverzicht
Bio-Techne Corporation, samen met haar dochterondernemingen, ontwikkelt, produceert en verkoopt life science reagentia, instrumenten en diensten voor de onderzoeks-, diagnostiek- en bioprocessingmarkten wereldwijd. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor TECH uit onze risicocontroles.
TECH Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bio-Techne Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$72.33 |
| 52 Week Hoogtepunt | US$72.62 |
| 52 Week Laag | US$43.20 |
| Bèta | 1.28 |
| 1 maand verandering | -0.083% |
| 3 maanden verandering | 24.84% |
| 1 Jaar Verandering | 40.39% |
| 3 jaar verandering | 2.06% |
| 5 jaar verandering | -45.72% |
| Verandering sinds IPO | 11,190.54% |
Recent nieuws en updates
Recent updates
Narratiefupdate • Aug 12
TECH: Acquisition Offer And Resilient Pharma Demand Will Support A Balanced Outlook
Analysts have lifted their price target for Bio-Techne from about $61 to roughly $70, citing updated assumptions for revenue growth, profit margins and future P/E. These changes shift their fair value framework higher in spite of a slightly different discount rate outlook.
Narratiefupdate • Jul 29
TECH: Merger Premium And Deal Uncertainty Will Restrain Future Earnings Appeal
Analysts have nudged their price target for Bio-Techne higher to reflect a shift in fair value from $55.05 to $56.51. This change is supported by updated assumptions for revenue growth, profit margins and future P/E levels, as well as a slightly lower discount rate.
Narratiefupdate • Jul 15
TECH: AI Protein Expansion And Portfolio Rebrand Will Support Balanced Long-Term Upside
Analysts have reduced their price target on Bio-Techne to $73 from $75, reflecting updated assumptions about the balance between revenue growth expectations, lower projected profit margins, and a slightly higher future P/E multiple. What’s in the News for Bio-Techne Bio-Techne and Merck KGaA agreed to a definitive acquisition deal in which Merck KGaA plans to acquire Bio-Techne for US$73 per share in cash, valuing the company at about US$11.5b and implying an enterprise value of roughly US$11.3b, with the transaction subject to regulatory and shareholder approvals and customary closing conditions.Narratiefupdate • Jul 01
TECH: Pending Merger Premium Will Constrain Future Earnings Appeal
Bio-Techne's updated analyst price target has been trimmed from about $56.78 to $55.05, as analysts factor in slightly higher assumed revenue growth and P/E levels, along with modestly lower profit margin estimates. What’s in the News for Bio-Techne Merck KGaA agreed to acquire Bio-Techne in an all cash transaction valued between US$11.3b and US$11.5b, which Merck states represents about a 36% premium to Bio-Techne’s trading price at announcement.Analyse-artikel • Jun 18
Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration
Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits...Narratiefupdate • Jun 17
TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin Upside
Analysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.Narratiefupdate • Jun 03
TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward Outlook
Analysts have lowered their price target on Bio-Techne from $75.25 to $61.42, citing updated assumptions that include slightly lower revenue growth, modestly higher profit margins, and a reduced future P/E multiple. What's in the News Bio-Techne stock rallied about 12% over a recent five day period, adding roughly US$780 million in market value to reach around US$7.5b in market capitalization, according to recent coverage.Narratiefupdate • May 12
TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future Upside
Analysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).Narratiefupdate • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.Narratiefupdate • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).Narratiefupdate • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).Narratiefupdate • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).Narratiefupdate • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.Analyse-artikel • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...Narratiefupdate • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).Narratiefupdate • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking AlphaNarratiefupdate • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).Narratiefupdate • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).Narratiefupdate • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.Narratiefupdate • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).Analyse-artikel • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...Narratiefupdate • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.Narratiefupdate • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.Narratiefupdate • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking AlphaRendement voor aandeelhouders
| TECH | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 0.1% | 5.5% | -1.1% |
| 1Y | 40.4% | 30.9% | 11.7% |
Rendement versus industrie: TECH overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 30.9 % opleverde.
Rendement versus markt: TECH overtrof de US markt, die het afgelopen jaar een rendement opleverde van 11.7 %.
Prijsvolatiliteit
| TECH volatility | |
|---|---|
| TECH Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: TECH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van TECH is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1976 | 3,000 | Kim Kelderman | www.bio-techne.com |
Bio-Techne Corporation ontwikkelt, produceert en verkoopt, samen met haar dochterondernemingen, reagentia, instrumenten en diensten op het gebied van de levenswetenschappen voor de wereldwijde markten voor onderzoek, diagnostiek en bioprocessen. Het bedrijf is actief in twee segmenten: Protein Sciences en Diagnostics and Spatial Biology. Het segment Protein Sciences ontwikkelt en produceert biologische reagentia die worden gebruikt in diverse aspecten van life science-onderzoek, diagnostiek en cel- en gentherapie, zoals cytokines en groeifactoren, antilichamen, kleine moleculen, weefselkweeksera en celselectietechnologieën.
Bio-Techne Corporation Samenvatting
| TECH fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$11.34b |
| Inkomsten(TTM) | US$181.84m |
| Inkomsten(TTM) | US$1.22b |
62.4x
Koers/Winstverhouding9.3x
P/S-verhoudingIs TECH overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TECH resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.22b |
| Kosten van inkomsten | US$410.16m |
| Brutowinst | US$804.88m |
| Overige uitgaven | US$623.04m |
| Inkomsten | US$181.84m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.16 |
| Brutomarge | 66.24% |
| Nettowinstmarge | 14.97% |
| Schuld/Eigen Vermogen Verhouding | 9.5% |
Hoe presteerde TECH op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.4%
Huidig dividendrendement27%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/16 20:11 |
| Aandelenkoers aan het einde van de dag | 2026/09/16 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2026/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bio-Techne Corporation wordt gevolgd door 26 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Robert Bamberger | Baird |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |